Back to Search
DR. DAVID P. BRADLEY M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1679531016IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
1805(WI)
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
35.121468(OH)
Education
WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE
Class of 2005
Clinical Trials (2)
2
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Alterations in energy balance following exenatide administration.
PMID 22735035·Appl Physiol Nutr Metab·2012
3-trial
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
PMID 20413733·Arterioscler Thromb Vasc Biol·2010
3-trial
Prediabetes: the importance of early identification and intervention.
PMID 20675976·Postgrad Med·2010
6-review
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
PMID 20876408·Arch Intern Med·2010
4-observational
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.
PMID 18332269·Circulation·2008
8-other
Relationship between beta-cell mass and diabetes onset.
PMID 18834430·Diabetes Obes Metab·2008
7-preclinical
Weight loss therapy improves pancreatic endocrine function in obese older adults.
PMID 18388888·Obesity (Silver Spring)·2008
2-rct
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
PMID 17468345·Diabetes Care·2007
2-rct
Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
PMID 16755277·Pharmacogenomics J·2007
8-other
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
PMID 15111485·Diabetes·2004
3-trial
Accurate assessment of beta-cell function: the hyperbolic correction.
PMID 11815482·Diabetes·2002
6-review
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
PMID 18814988·Magn Reson Imaging·2009
7-preclinical
Temporal discrimination threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia.
PMID 19525326·Brain·2009
8-other
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
PMID 17458919·NMR Biomed·2008
7-preclinical
Annihilation of an AB/BA interface pair in superfluid helium-3 as a simulation of cosmological brane interaction.
PMID 18534941·Philos Trans A Math Phys Eng Sci·2008
8-other
Fluctuations and Correlations of Pure Quantum Turbulence in Superfluid 3He-B.
PMID 18764468·Phys Rev Lett·2008
8-other
Pathogens promote plant diversity through a compensatory response.
PMID 18312409·Ecol Lett·2008
8-other
Actuation of mobility intentions among the young-old: an event-history analysis.
PMID 18483431·Gerontologist·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1150 COCOA AVE
HERSHEY, PA 17033 - Phone
- (717) 531-6015
Quick Facts
- NPI
- 1679531016
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 21
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile